Sutro Biopharma (STRO) Operating Expenses (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Operating Expenses data on file, last reported at $49.7 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses fell 37.93% year-over-year to $49.7 million; the trailing twelve-month figure through Dec 2025 stood at $260.9 million (down 13.19% YoY), and the FY2025 full-year result was $260.9 million, down 13.19% from the prior year.
• Operating Expenses retreated to $49.7 million in Q4 2025, from $58.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $85.9 million in Q1 2025 to a low of $33.7 million in Q1 2021.
• A 5-year average of $58.1 million and a median of $57.2 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 51.87% in 2021 and plunged 37.93% in 2025, its largest moves.
• Tracing STRO's Operating Expenses over 5 years: stood at $45.7 million in 2021, then rose by 26.62% to $57.9 million in 2022, then increased by 21.98% to $70.6 million in 2023, then grew by 13.46% to $80.1 million in 2024, then plunged by 37.93% to $49.7 million in 2025.
• Business Quant data shows STRO's Operating Expenses at $49.7 million in Q4 2025, $58.2 million in Q3 2025, and $67.1 million in Q2 2025.